Categories
Change Password!
Reset Password!
A retrospective, observational trial was performed to investigate the efficacy and safety of erenumab (a monoclonal antibody that blocks the calcitonin gene–related peptide receptor) in individuals with chronic migraine and medication overuse headache in a real-life setting up to one year.
Erenumab was found to be effective
and safe to manage patients suffering from chronic migraine complicated with
medication overuse headache.
A
retrospective, observational trial was performed to investigate the efficacy
and safety of erenumab (a monoclonal antibody that blocks the calcitonin
gene–related peptide receptor) in individuals with chronic migraine and medication
overuse headache in a real-life setting up to one year.
Data
concerning 81 participants treated with erenumab were retrospectively assessed
in this 12-month real-life trial. The variables monitored every three months
were: (i) headache intensity (numeric rating scale score) (ii) Self-Reported
Instrument to Assess Work-Related Difficulties in Patients With Migraine
(HEADWORK) scores, (iii) average number of painkillers taken per month
(analgesic consumption), (iv) 6-item Headache Impact Test (v) mean number of
days with painkiller consumption (number of days on medication), and (vi) mean
number of headache days per month (headache index).
The analgesic consumption, headache index, and the number of days on medication and the numeric rating scale, 6-item Headache Impact Test, and HEADWORK scores were considerably reduced at every time point from the third month onward in comparison with baseline. No substantial differences were witnessed between individuals who underwent painkiller detoxification prior to initiating erenumab and those who did not.
There were no vital differences between individuals receiving erenumab therapy
in combination with other preventive therapies and the individuals taking only
erenumab therapy. In this study, five participants dropped out due to adverse
events, that were found to resolve after ceasing erenumab. Painkiller
withdrawal and the link with other preventive therapies appeared to be of no
use.
Erenumab
appears to be a promising agent to treat chronic migraine complicated with medication
overuse headache.
Neurological Sciences
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study
Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study Maria Michela Cainazzo et al.
Comments (0)